Keratoplasty postoperative treatment update

MacHiko Shimmura-Tomita, Shigeto Shimmura, Yoshiyuki Satake, Seika Shimazaki-Den, Masahiro Omoto, Kazuo Tsubota, Jun Shimazaki

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Immunosuppressive therapy is the main postoperative treatment for keratoplasty, but there are considerable differences in protocols for the use of steroids and other immunosuppressants. Therefore, we conducted 2 prospective randomized clinical trials and 1 prospective nonrandomized clinical trial on keratoplasty postoperative treatment. One study evaluated the efficacy and safety of long-term topical corticosteroids after a penetrating keratoplasty was performed. Patients who underwent keratoplasty and maintained graft clarity for >1 year were randomly assigned to either a steroid or a no-steroid group. At the 12-month follow-up, the no-steroid group developed significantly more endothelial rejection than did the steroid group. A second study elucidated the effectiveness and safety of systemic cyclosporine in high-risk corneal transplantation. The patients were assigned to a systemic cyclosporine or control group. At a mean follow-up of 42.7 months, no difference was observed in the endothelial rejection rates and graft clarity loss between the 2 groups. A third study elucidated the effectiveness and the safety of systemic tacrolimus in high-risk corneal transplantation. Of 11 consecutive eyes decompensated despite systemic cyclosporine treatment, there was no irreversible rejection in eyes treated with tacrolimus, which was significantly better than in previous penetrating keratoplasty with systemic cyclosporine treatment. Prognosis after keratoplasty in patients with keratoconus is relatively good, but special attention is required for patients with atopic dermatitis. Postkeratoplasty atopic sclerokeratitis (PKAS) is a severe form of sclerokeratitis after keratoplasty in atopic patients. Our retrospective study showed that 35 eyes of 29 patients from a total of 247 keratoconus eyes undergoing keratoplasty were associated with atopic dermatitis, of which 6 eyes of 5 patients developed PKAS. Eyes with PKAS had a significantly higher incidence of atopic blepharitis and preoperative corneal neovascularization, and therefore, we suggest systemic corticosteroids or cyclosporine to prevent PKAS in such high-risk cases.

Original languageEnglish
JournalCornea
Volume32
Issue number11 SUPPL
DOIs
Publication statusPublished - 2013 Nov

Fingerprint

Corneal Transplantation
Cyclosporine
Steroids
Keratoconus
Penetrating Keratoplasty
Tacrolimus
Therapeutics
Immunosuppressive Agents
Safety
Adrenal Cortex Hormones
Blepharitis
Corneal Neovascularization
Graft Rejection
Atopic Dermatitis
Randomized Controlled Trials
Retrospective Studies
Transplants
Control Groups
Incidence

Keywords

  • atopic dermatitis
  • cyclosporine
  • keratoplasty
  • steroid
  • tacrolimus

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Shimmura-Tomita, M., Shimmura, S., Satake, Y., Shimazaki-Den, S., Omoto, M., Tsubota, K., & Shimazaki, J. (2013). Keratoplasty postoperative treatment update. Cornea, 32(11 SUPPL). https://doi.org/10.1097/ICO.0b013e3182a2c937

Keratoplasty postoperative treatment update. / Shimmura-Tomita, MacHiko; Shimmura, Shigeto; Satake, Yoshiyuki; Shimazaki-Den, Seika; Omoto, Masahiro; Tsubota, Kazuo; Shimazaki, Jun.

In: Cornea, Vol. 32, No. 11 SUPPL, 11.2013.

Research output: Contribution to journalArticle

Shimmura-Tomita, M, Shimmura, S, Satake, Y, Shimazaki-Den, S, Omoto, M, Tsubota, K & Shimazaki, J 2013, 'Keratoplasty postoperative treatment update', Cornea, vol. 32, no. 11 SUPPL. https://doi.org/10.1097/ICO.0b013e3182a2c937
Shimmura-Tomita M, Shimmura S, Satake Y, Shimazaki-Den S, Omoto M, Tsubota K et al. Keratoplasty postoperative treatment update. Cornea. 2013 Nov;32(11 SUPPL). https://doi.org/10.1097/ICO.0b013e3182a2c937
Shimmura-Tomita, MacHiko ; Shimmura, Shigeto ; Satake, Yoshiyuki ; Shimazaki-Den, Seika ; Omoto, Masahiro ; Tsubota, Kazuo ; Shimazaki, Jun. / Keratoplasty postoperative treatment update. In: Cornea. 2013 ; Vol. 32, No. 11 SUPPL.
@article{f31bb5faa65045eb8e5f389720b6c565,
title = "Keratoplasty postoperative treatment update",
abstract = "Immunosuppressive therapy is the main postoperative treatment for keratoplasty, but there are considerable differences in protocols for the use of steroids and other immunosuppressants. Therefore, we conducted 2 prospective randomized clinical trials and 1 prospective nonrandomized clinical trial on keratoplasty postoperative treatment. One study evaluated the efficacy and safety of long-term topical corticosteroids after a penetrating keratoplasty was performed. Patients who underwent keratoplasty and maintained graft clarity for >1 year were randomly assigned to either a steroid or a no-steroid group. At the 12-month follow-up, the no-steroid group developed significantly more endothelial rejection than did the steroid group. A second study elucidated the effectiveness and safety of systemic cyclosporine in high-risk corneal transplantation. The patients were assigned to a systemic cyclosporine or control group. At a mean follow-up of 42.7 months, no difference was observed in the endothelial rejection rates and graft clarity loss between the 2 groups. A third study elucidated the effectiveness and the safety of systemic tacrolimus in high-risk corneal transplantation. Of 11 consecutive eyes decompensated despite systemic cyclosporine treatment, there was no irreversible rejection in eyes treated with tacrolimus, which was significantly better than in previous penetrating keratoplasty with systemic cyclosporine treatment. Prognosis after keratoplasty in patients with keratoconus is relatively good, but special attention is required for patients with atopic dermatitis. Postkeratoplasty atopic sclerokeratitis (PKAS) is a severe form of sclerokeratitis after keratoplasty in atopic patients. Our retrospective study showed that 35 eyes of 29 patients from a total of 247 keratoconus eyes undergoing keratoplasty were associated with atopic dermatitis, of which 6 eyes of 5 patients developed PKAS. Eyes with PKAS had a significantly higher incidence of atopic blepharitis and preoperative corneal neovascularization, and therefore, we suggest systemic corticosteroids or cyclosporine to prevent PKAS in such high-risk cases.",
keywords = "atopic dermatitis, cyclosporine, keratoplasty, steroid, tacrolimus",
author = "MacHiko Shimmura-Tomita and Shigeto Shimmura and Yoshiyuki Satake and Seika Shimazaki-Den and Masahiro Omoto and Kazuo Tsubota and Jun Shimazaki",
year = "2013",
month = "11",
doi = "10.1097/ICO.0b013e3182a2c937",
language = "English",
volume = "32",
journal = "Cornea",
issn = "0277-3740",
publisher = "Lippincott Williams and Wilkins",
number = "11 SUPPL",

}

TY - JOUR

T1 - Keratoplasty postoperative treatment update

AU - Shimmura-Tomita, MacHiko

AU - Shimmura, Shigeto

AU - Satake, Yoshiyuki

AU - Shimazaki-Den, Seika

AU - Omoto, Masahiro

AU - Tsubota, Kazuo

AU - Shimazaki, Jun

PY - 2013/11

Y1 - 2013/11

N2 - Immunosuppressive therapy is the main postoperative treatment for keratoplasty, but there are considerable differences in protocols for the use of steroids and other immunosuppressants. Therefore, we conducted 2 prospective randomized clinical trials and 1 prospective nonrandomized clinical trial on keratoplasty postoperative treatment. One study evaluated the efficacy and safety of long-term topical corticosteroids after a penetrating keratoplasty was performed. Patients who underwent keratoplasty and maintained graft clarity for >1 year were randomly assigned to either a steroid or a no-steroid group. At the 12-month follow-up, the no-steroid group developed significantly more endothelial rejection than did the steroid group. A second study elucidated the effectiveness and safety of systemic cyclosporine in high-risk corneal transplantation. The patients were assigned to a systemic cyclosporine or control group. At a mean follow-up of 42.7 months, no difference was observed in the endothelial rejection rates and graft clarity loss between the 2 groups. A third study elucidated the effectiveness and the safety of systemic tacrolimus in high-risk corneal transplantation. Of 11 consecutive eyes decompensated despite systemic cyclosporine treatment, there was no irreversible rejection in eyes treated with tacrolimus, which was significantly better than in previous penetrating keratoplasty with systemic cyclosporine treatment. Prognosis after keratoplasty in patients with keratoconus is relatively good, but special attention is required for patients with atopic dermatitis. Postkeratoplasty atopic sclerokeratitis (PKAS) is a severe form of sclerokeratitis after keratoplasty in atopic patients. Our retrospective study showed that 35 eyes of 29 patients from a total of 247 keratoconus eyes undergoing keratoplasty were associated with atopic dermatitis, of which 6 eyes of 5 patients developed PKAS. Eyes with PKAS had a significantly higher incidence of atopic blepharitis and preoperative corneal neovascularization, and therefore, we suggest systemic corticosteroids or cyclosporine to prevent PKAS in such high-risk cases.

AB - Immunosuppressive therapy is the main postoperative treatment for keratoplasty, but there are considerable differences in protocols for the use of steroids and other immunosuppressants. Therefore, we conducted 2 prospective randomized clinical trials and 1 prospective nonrandomized clinical trial on keratoplasty postoperative treatment. One study evaluated the efficacy and safety of long-term topical corticosteroids after a penetrating keratoplasty was performed. Patients who underwent keratoplasty and maintained graft clarity for >1 year were randomly assigned to either a steroid or a no-steroid group. At the 12-month follow-up, the no-steroid group developed significantly more endothelial rejection than did the steroid group. A second study elucidated the effectiveness and safety of systemic cyclosporine in high-risk corneal transplantation. The patients were assigned to a systemic cyclosporine or control group. At a mean follow-up of 42.7 months, no difference was observed in the endothelial rejection rates and graft clarity loss between the 2 groups. A third study elucidated the effectiveness and the safety of systemic tacrolimus in high-risk corneal transplantation. Of 11 consecutive eyes decompensated despite systemic cyclosporine treatment, there was no irreversible rejection in eyes treated with tacrolimus, which was significantly better than in previous penetrating keratoplasty with systemic cyclosporine treatment. Prognosis after keratoplasty in patients with keratoconus is relatively good, but special attention is required for patients with atopic dermatitis. Postkeratoplasty atopic sclerokeratitis (PKAS) is a severe form of sclerokeratitis after keratoplasty in atopic patients. Our retrospective study showed that 35 eyes of 29 patients from a total of 247 keratoconus eyes undergoing keratoplasty were associated with atopic dermatitis, of which 6 eyes of 5 patients developed PKAS. Eyes with PKAS had a significantly higher incidence of atopic blepharitis and preoperative corneal neovascularization, and therefore, we suggest systemic corticosteroids or cyclosporine to prevent PKAS in such high-risk cases.

KW - atopic dermatitis

KW - cyclosporine

KW - keratoplasty

KW - steroid

KW - tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=84885965318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885965318&partnerID=8YFLogxK

U2 - 10.1097/ICO.0b013e3182a2c937

DO - 10.1097/ICO.0b013e3182a2c937

M3 - Article

C2 - 24104936

AN - SCOPUS:84885965318

VL - 32

JO - Cornea

JF - Cornea

SN - 0277-3740

IS - 11 SUPPL

ER -